A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Autor: Burnett, Alan K. ^*, Russell, Nigel H., Hills, Robert K., Kell, Jonathan, Cavenagh, Jamie, Kjeldsen, Lars, McMullin, Mary-Frances, Cahalin, Paul, Dennis, Mike, Friis, Lone, Thomas, Ian F., Milligan, Don, Clark, Richard E.

Publikováno v: In Blood 18 June 2015 125(25):3878-3885

James Harper Milligan

Autor: Milligan, Don

Publikováno v: BMJ: British Medical Journal, 2008 Feb . 336(7640), 395-395.

Externí odkaz: https://www.jstor.org/stable/20508999

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Autor: Anderson, Richard A, Remedios, Rachel, Kirkwood, Amy A, Patrick, Pip, Stevens, Linsey, Clifton-Hadley, Laura, Roberts, Tom, Hatton, Chris, Kalakonda, Nagesh, Milligan, Don W, McKay, Pam, Rowntree, Clare, Scott, Fiona M, Johnson, Peter W M

Publikováno v: Anderson, R A, Remedios, R, Kirkwood, A A, Patrick, P, Stevens, L, Clifton-Hadley, L, Roberts, T, Hatton, C, Kalakonda, N, Milligan, D W, McKay, P, Rowntree, C, Scott, F M & Johnson, P W M 2018, ' Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 19, no. 10, pp. 1328-1337 . https://doi.org/10.1016/S1470-2045(18)30500-X
The Lancet. Oncology

BACKGROUND: Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::e7c8436c894d056e2eb3f67016a4b05c
https://pubmed.ncbi.nlm.nih.gov/30220624

Modeling Costs and Cost-Effectiveness of Different CMV Management Strategies in Liver Transplant Recipients as a Support for Current and Future Decision Making

Autor: Annemans, Lieven, Moeremans, Karen, Mutimer, David, Schneeberger, Helmut, Milligan, Don, Kubin, Maria

Publikováno v: In Value in Health 2002 5(4):347-358

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

Autor: Hillmen, Peter, Cohen, Dena R., Cocks, Kim, Pettitt, Andrew, Sayala, Hazem A., Rawstron, Andy C., Kennedy, Daniel B., Fegan, Christopher, Milligan, Don W., Radford, John, Mercieca, Jane, Dearden, Claire, Ezekwisili, Raphael, Smith, Alexandra F., Brown, Julia, Booth, Gillian A., Varghese, Abraham M., Pocock, Christopher

Publikováno v: Hillmen, P, Cohen, D R, Cocks, K, Pettitt, A, Sayala, H A, Rawstron, A C, Kennedy, D B, Fegan, C, Milligan, D W, Radford, J, Mercieca, J, Dearden, C, Ezekwisili, R, Smith, A F, Brown, J, Booth, G A, Varghese, A M & Pocock, C 2011, ' A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia ', British Journal of Haematology, vol. 152, no. 5, pp. 570-578 . https://doi.org/10.1111/j.1365-2141.2010.08317.x

Combination fludarabine (F), cyclophosphamide (C) and rituximab (R) is the standard front-line therapy in chronic lymphocytic leukaemia (CLL), but appropriate treatment of relapsed/refractory CLL is less clear. Combined FC and mitoxantrone (M) has be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::12fb955e3901642c18668251c51b0766
https://doi.org/10.1111/j.1365-2141.2010.08317.x